UNSPSC 51351636: Estradiol cypionate/medroxyprogesterone acetate

Estradiol cypionate/medroxyprogesterone acetate (EC/MPA) is a form of combined injectable birth control.[2] It contains estradiol cypionate (EC), estrogen, and medroxyprogesterone acetate (MPA), a progestin.

UNSPSC 51351636 Estradiol cypionate/medroxyprogesterone acetate, a Commodity code, shows no relevant recent state and local procurement activity. The nine opportunities posted in the recent-opportunities block span EMS software platforms (Collier County), long-term care pharmacy services (Dane County), procurement conferences and networking events (Clay County and Marion County), aquatic facility operations (Palm Bay), pharmacy benefits programs (District of Columbia), naloxone distribution (Washington County and Seminole County), on-call technical services (Owensboro), group purchasing organization membership (San Mateo County), BLS/ALS pharmaceutical supplies and vending systems (Tucson), community mental health pharmacy services (West Texas Centers), drug standards for forensic analysis (Pinellas County), opioid settlement grant administration (Bernalillo County), and a department relocation notice (Williamson County). None of these solicitations involve the procurement of estradiol cypionate/medroxyprogesterone acetate as a pharmaceutical product for purchase or distribution. The code's nominal scope—a specific hormone-based medication—does not align with any work actually being solicited under this classification in the recent state and local market.

Estradiol cypionate/medroxyprogesterone acetate procurement does not appear in current state and local opportunities. If purchasing decisions for this medication are made, they are either embedded within broader pharmaceutical services RFPs (such as the Dane County long-term care pharmacy services opportunity or West Texas Centers mental health pharmacy contract, both of which likely include hormonal medications within comprehensive formularies) or are being transacted through standing state pharmaceutical contracts, cooperative purchasing agreements, or direct vendor relationships not captured in the recent-opportunities dataset. Business development professionals should monitor broader pharmacy and pharmaceutical services solicitations where this commodity may be specified as a line item rather than pursue standalone opportunities under this code designation.